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Role of interventions for atherosclerotic renal
artery stenoses
Vikram S. Kashyap, MD,a Fabrice Schneider, MD,b and Jean-Baptiste Ricco, MD, PhD,b Cleveland, Ohio;
and Poitiers, France
The role of and indications for interventions for renal artery stenosis have long been a hot topic of debate. Despite numerous
reports and studies over the years, there remain many unanswered questions. Among them are: Who should be intervened
upon? What should be the objectives of intervention? What is the optimal mode of intervention? More recently, several
randomized studies have attempted to answer some of these basic questions, but unfortunately have left many unanswered
questions. In the following debate, the authors consider the existing literature and attempt to convince us that the majority,
or the minority, of patients with renal artery stenoses should be intervened upon. (J Vasc Surg 2011;54:563-70.)
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dPART I: THE VAST MAJORITY OF PATIENTS
WITH RENAL ARTERY STENOSES REQUIRE
INTERVENTION
Vikram S. Kashyap, MD, Cleveland, Ohio
Introduction. The debate position given to this au-
thor may on first glance seem to be untenable. I hope to
convince you that the opposite stance of not treating pa-
tients with renal artery stenosis (RAS) neglects the oppor-
tunity to help some patients with correctable hypertension
and renal dysfunction. Frankly, either debate position is
difficult to defend given our dearth of solid information in
the arena of renovascular disease. As a medical community,
we have scant evidence on the natural history of RAS and
the kidneys these arteries are supplying. Furthermore, the
available data are far from convincing especially given the
flawed trial designs inmost of the prospective trials. Clearly,
further study on renovascular disease may lead us to better
medical management, patient selection for intervention,
and technical success in those patients that are intervened
upon. I do not believe a global position of benign neglect of
renal artery disease will be in the best interest of patients
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doi:10.1016/j.jvs.2011.06.003ith this morbid condition. There are some current posits
hat require re-examination. The following widely held
yths need scrutiny.
Myth #1. Atherosclerosis in the renal arteries is
enign. In every arterial bed, the severe consequences of
rterial narrowing secondary to atherosclerosis are recog-
ized. The initiation and progression of atherogenesis,
laque rupture, thrombosis, embolization, dissection, and
esultant end-organ deterioration is well delineated in arte-
ial beds from the skull to the toe. For instance, the process
f discovery that extracranial cerebrovascular disease caused
rtery-to-artery embolization leading to stroke took de-
ades.1 Furthermore, treatment of the offending lesion to
revent further stroke and death required rigorous ran-
omized controlled trials first in symptomatic patients.2
urgical treatment in the form of endarterectomy removes
he plaque leading to embolization and was found better
han medical therapy in the long-term stroke-free survival
f asymptomatic patients3 in the largest surgical trial to
ate.4 The limb and life-saving treatment of peripheral
therosclerosis is also well documented.5 Similarly, the
ecognition and timely management of patients with coro-
ary thrombosis is well recognized as life-saving by both
edical professionals and laypersons.
Why should the kidneys be different? The natural
istory of RAS is variable. But a significant fraction of
atients with RAS have progressive narrowing of the inflow
rtery to the functioning renal mass. Using Doppler scan
ollow-up, Zierler et al6 showed renal arteries with signifi-
ant stenoses (60%) have approximately a 20% progres-
ion of disease per year with 11% progressing to renal
cclusion within 2 years. Similarly, using ultrasound scan to
ocument renal size, Caps et al7 showed progression to
enal atrophy in patients with worsening RAS.
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August 2011564 Kashyap et alIt is estimated that chronic kidney disease affects 11% of
the adult population in the United States with nearly
400,000 patients with end-stage renal failure. The morbid-
ity and mortality of end-stage renal disease is staggering
with US annual mortality rates of 20%.8 Even lesser
degrees of chronic kidney disease can have significant con-
sequences as the risk of death increases as the glomerular
filtration rate (GFR) falls.9 Furthermore, reduced GFR is
independently associated with the cardiovascular morbidity
and hospitalization with severe renal impairment (GFR
30mL/min/1.73m2). Despite the prevalence of chronic
kidney disease, the relationship to RAS remains unclear. A
significant fraction of patients on hemodialysis have renal
vascular disease implicating that RAS may be an underap-
preciated component of renal failure.10
Myth #2. Patients with hypertension and renal
artery stenosis have renovascular hypertension. One of
the critical problems in assessing patients with RAS is the
unclear relationship with concomitant hypertension. Gold-
blatt et al’s11 compelling studies helped the medical com-
munity understand the causal relationship of RAS to hyper-
tension over 70 years ago. This led to several reports of
curing hypertension by surgical revascularization a few
years later. In pediatric or young adult populations with
congenital or vasculitic causes of RAS, hypertension is
closely aligned to the degree of unilateral RAS. With in-
creasing unilateral stenosis, neurohormonal changes occur
resulting in increased angiotensin II-induced blood pres-
sure elevation. In older populations, essential (or primary)
hypertension is rampant and appraising whether the RAS is
a bystander or the culprit can be challenging for even the
most experienced practitioner. A cavalier attitude by some
is that in our current limitations of understanding this
relationship, the only way to tell is the response after
intervention. That is, treat everyone, help a few. Clearly,
this position of “drive-by” stenting can lead to inappropri-
ate use of technology, increased costs, and the real possi-
bility of patient harm in cases of inadvertent renal injury.
Patients with severe hypertension with episodes of hy-
pertensive crises seem to be the best candidates for RAS
intervention.12 The severity of hypertension may be seen as
the need for increasing antihypertensive agents, increased
dosage or frequency of medication, and sudden worsening
in blood pressure control in an otherwise stable patient.
Despite a plethora of studies to try to understand this
relationship of RAS and hypertension, most studies (ie,
renal vein renin sampling) are not sufficiently sensitive or
specific to clearly implicate the RAS as the etiologic factor
for the hypertension. A test with prognostic value in this
arena will allow careful selection of patients that require
intervention. Last, the current data on blood pressure
reduction in trials are grossly estimated by the number of
medications and/or reduction in dose as a surrogate to
actual blood pressure measurements. The latter is a widely
fluctuating physiological parameter13 and deserves a more
precise assessment. sMyth #3. Ischemic nephropathy is any patient with an
scalating creatinine and bilateral renal artery stenosis. As
pposed to unilateral RAS and resultant renovascular hy-
ertension, bilateral RAS or stenosis in the artery leading to
single functioning kidney may lead to renal function loss.
enovascular hypertension may be overdiagnosed, but
AS causing renal insufficiency and eventual renal loss may
e underappreciated and consequently undertreated.10,14
his condition called “ischemic nephropathy” can be
reated and leads to gratifying improvement in renal func-
ion. However, the tools to assess this in our current
ractice are the poorly sensitive serum creatinine (sCr), the
FR with calculations often based on sCr, and nuclear
edicine testing where the images and interpretation can
ometimes be challenging and lead to differences in subjec-
ive impression between observers.
Unfortunately, most patients with “ischemic nephrop-
thy” presumably have renal function decline secondary to
nrelated chronic renal disease from intrinsic renal glomer-
lar loss secondary to a host of systemic processes. This may
nclude inflammatory conditions and oxidative stress.15
Similar to myth #2, the likelihood of understanding in
particular patient whether renal function decline is due to
AS is often difficult. Many experienced practitioners have
ad the gratifying situation of observing rapid improve-
ent in renal function after treating severe RAS to a single
unctioning kidney where the serum markers clearly delin-
ate residual renal function. Likewise, the experience of
atients with no improvement in their renal function de-
pite a technically successful procedure is not uncommon.
alvage of the kidneys is best predicted by the downward
lope of GFR or renal function before intervention.16,17
ther prognostic modalities to identify renal mass retrieval
ay be novel magnetic resonance-basedmethods to under-
tand the perfusion deficit in patients with ischemic ne-
hropathy.18 Novel technologies and assays would allow us
o determine an infarcted renal mass from one that is
schemic, analogous to stress testing and biomarkers in the
oronary beds.
Myth #4. Renal stenting is an easy procedure to do
ell. For the purposes of this debate, we are assuming
ntervention of the renal arteries means endovascular inter-
ention. There is rich literature on the benefits of surgical
evascularization of the renal arteries.12,13 Surgical revascu-
arization for retrieval of renal function can be accom-
lished with documented durable long-term results in cen-
ers of excellence with a dedicated interest in renovascular
urgery.19,20 However, this has largely been supplanted by
ndovascular means21 because of the perceived lower initial
orbidity of a purely percutaneous procedure as opposed
o open revascularization in an elderly population with
ultiple comorbidities.
Technical advances have also spurred widespread adop-
ion of endovascular treatment of RAS. Despite the rapid
ncrease in renal stenting, trial data have documented the
arm that can occur to the kidneys that we are trying to
rotect from deterioration. The kidney does not have the
ame discrete functional areas that would alert a clinician to
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Volume 54, Number 2 Kashyap et al 565kidney decline after intervention other than where serious
harm has occurred because of large emboli, renal infarction,
dissection, reperfusion injury, or contrast-induced renal
failure. Some of these may happen more than we realize.
Some possible technical adjuncts that prevent these com-
plications include adopting a 6Fr platform for intervention
with the use of 0.014-inch guidewires and stent systems,
rapid-exchange systems, using a distal protection device,
using a “no touch” technique, anticoagulation/direct
thrombin inhibition, and routine periprocedure double-
antiplatelet therapy with aspirin and clopidogrel. Clearly, in
other arterial beds, a distal protection device can be used to
capture atheroembolic debris before reaching the end or-
gan that we are trying to protect.22 The use of a distal
protection device during renal intervention makes intuitive
sense given the capture of embolic debris in a significant
fraction of cases.23,24 Additional evidence that atheroem-
bolic material that could cause renal parenchymal damage
has been obtained via an ex vivo study using human arterial
plaque specimens.25 Currently, the outcome of renal per-
cutaneous transluminal angioplasty and stenting with a
distal protection device is being evaluated in the National
Institutes of Health-supported randomized controlled
Cardiovascular Outcomes in Renal Atherosclerotic Lesions
(CORAL) trial.26
Myth #5. The data from randomized trials are
clear-cut. My debate opponent will try to convince you
that multiple randomized controlled trials clearly show no
benefit from renal artery stenting. One thing is clear: no
benefit can be obtained in patients poorly selected for
intervention. Another critical point: any benefit from an
intervention can be negated by the poor performance of the
procedure.
In the recent STAR publication, the investigators ran-
domized 140 patients to medical therapy or renal artery
stenting for atherosclerotic disease in the renal arteries at 10
European medical centers.27 Patients were eligible for in-
clusion if creatinine clearance was 80 mL/minute per
1.73 m2 and they had a 50% or greater stenosis. The
primary endpoint was a 20% or greater fall in creatinine
clearance. This occurred in 16% of the stent group and 22%
of the medication group (PNS). The authors concluded
that stent placement had no clear benefit on preventing
renal function decline in this small study. Of note, only 46
of the 64 patients assigned to stenting actually had a stent
placed. Of great concern was that 12 of the 64 patients
(19%) did not get a stent because they had50% stenosis at
the time of angiography despite the preoperative imaging
(computed tomographic angiography, magnetic resonance
angiography) indicating a high-grade stenosis. One can
assume that the medical therapy group also had a large
fraction of patients with insignificant and benign RAS
(50%). The rates of complications in the stented group,
including two procedure-related deaths, one death from an
infected hematoma, one renal failure after kidney choles-
terol embolism, two technical failures, and 10 femoral
hematomas, paint a troubling picture in a group of 46 renal
stent procedures. oAngioplasty and Stent for Renal Artery Lesions is an
nternational, multicenter trial that enrolled 806 patients
nd randomized them to intervention or medical manage-
ent.28 The primary outcome was again renal function
easured as a reciprocal of the sCr level. The two groups
ad similar rates of renal events, cardiovascular events, and
eath, as will be outlined by our debate opponent. But, this
rial has many limitations. Of greatest concern were the
nclusion criteria of patients into the trial. Patients were
ligible for enrollment if they had atherosclerotic disease in
he renal arteries and were considered suitable for endovas-
ular revascularization. However, only 59% of enrolled
atients had an RAS 70% with essentially the remainder
aving 50% to 70% stenoses. Physicians did not enroll
atients if they thought that renal revascularization would
e beneficial—the exact target that any randomized con-
rolled trials in this arena should focus on. Thus, the
atients that we assume would have the greatest benefit
rom revascularization were excluded. Neither the medical
anagement nor the intervention techniques were stan-
ardized and there was no core laboratory to review the
mages and corroborate the renal artery stenoses treated. In
act, often the severity of the stenosis is overestimated by
he interventionalist when compared to the core laborato-
y’s nonbiased assessment.29 Thus, many of these patients
ay have actually had modest (ie, 50%) stenoses, rather
han critical stenoses to the kidney they were trying to
rotect. Seventeen percent of patients did not undergo
ntervention after angiography because the severity of RAS
y noninvasive methods was not confirmed on angiogra-
hy; one can assume a similar proportion of low-profile
esions in the medical group. Additionally, 40% of enrollees
ad sCr levels 150 mol/L (1.7 mg/dL), with a large
raction of these patients with normal creatinine and only
n an average 2.8 antihypertensive agents. What was the
ndication for treatment in these patients? In the 359
atients that actually underwent revascularization, 31 pa-
ients (9%) had complications. This included renal emboli-
ation,5 renal artery occlusion,4 renal artery perforation,4
emoral artery aneurysm,1 and cholesterol embolization3
eading to gangrene and amputation. With any revascular-
zation procedure for atherosclerosis, we are trying to
beat” the natural history of the disease. Patients that have
igh-grade renal artery lesions, rapidly falling GFR, and
tenoses to the whole renal mass (ie, bilateral renal stenoses,
tenosis to a single-functioning kidney) may benefit from
enal stenting. But, trials that enroll large fractions of the
atients with benign lesions and then have high complica-
ion rates cannot be expected to be successful.
ONCLUSIONS
With the current data available, one may not be able to
onclude that “vast majority of patients with renal artery
tenoses require intervention,” the provocative position
ssigned to this author. On the other hand, the position
the vast majority of patients with renal artery stenoses do
ot require intervention” leaves many patients without an
ption thatmay be kidney- and life-saving.We all agree that
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August 2011566 Kashyap et almore research is needed in this area. One day, clinicians will
be able to discern that a particular RAS is the culprit that
leads the kidney end organ to cause hypertension and/or
become ischemic and atrophy. In the interval, careful eval-
uation of patients with RAS and renal insufficiency by a
collaborative team of nephrologists and vascular specialists
seems to be warranted. This may offer patients the best
opportunity for long-term renal salvage and survival,
whether it be medical treatment or intervention.
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ART II: THE VAST MAJORITY OF PATIENTS
ITH ATHEROSCLEROTIC RENAL ARTERY
TENOSES DO NOT REQUIRE
NTERVENTION
Fabrice Schneider, MD, and Jean-Baptiste Ricco,
D, PhD, Poitiers, France
Introduction. The rate of percutaneous renal artery
ntervention among Medicare beneficiaries increased 2.4-
old in 2000 as compared with 1996 on the premise that
ssociated hypertension and renal function would be
ured.1 To date, however, recent randomized controlled
rials (RCTs) on primary stenting for atherosclerotic renal
rtery stenosis (ARAS) are not supporting evidence for its
se.2 The goal of this debate was to summarize the evi-
ence on percutaneous renal artery stenting for ARAS.
HE CLINICAL PROBLEM
The reported incidence of ARAS in the Medicare pop-
lation is 0.5% overall,3 but as these patients are often
symptomatic, the true frequency of ARAS is probably
igher. ARAS is associated with hypertension, chronic kid-
ey disease, and cardiac disorders, although it is not clear
hether these associations are causal.4 Nevertheless, pa-
ients with ARAS after adjustment for other traditional risk
actors, are at increased risk for cardiovascular events with a
isk of coronary event that is increased by a factor of two
nd markedly decreased survival.5 These outcomes are rare
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Volume 54, Number 2 Kashyap et al 567in patients with ARAS that are treated medically6 and
probably related to distribution and severity of atheroscle-
rosis in other vascular beds.7,8
EVALUATION
ARAS is suspected in patients with the onset of hyper-
tension after 50 years of age. Confirmation of the diagnosis
is made by imaging. Doppler scan measurement of renal
artery velocity provides an assessment of the severity of the
stenosis. Alternative methods include magnetic resonance
angiography, computed tomographic angiography, and
digital subtraction angiography with the use of small cath-
eters and limited amounts of contrast media. All these tests
are useful in confirming the diagnosis of ARAS, but Dr-
ieghe et al9 have shown that even if renal angiography and
color duplex ultrasound scans correlate well, both ap-
proaches tend to overestimate the ARAS severity when
compared with the measured trans-stenotic pressure gradi-
ent using 0.014 pressure wires. Again, none of these tech-
niques can establish the functional significance of ARAS.
Even the documentation of a trans-stenotic pressure gradi-
ent in ARAS does not necessarily mean that the given
stenosis is the cause of hypertension.
Risk factors and medical treatment. A major con-
founder related to the treatment of ARAS is competing risk
from other manifestations of atherosclerosis, including
stroke, acute coronary syndrome, and congestive heart
failure. The risk of these events is greater than the risk of
complications related specifically to ARAS. They reflect
widespread atherosclerotic disease elsewhere.10 In this con-
text, medical therapy remains the cornerstone of treatment
for ARAS. Multi-drug regimens are needed for blood pres-
sure control, including a renin-angiotensin-aldosterone in-
hibitor, alpha or beta-blocker, diuretic, and calcium chan-
nel antagonist. The demonstrated benefits of antiplatelet
therapy and statins in patients with atherosclerotic disease
also provide support for their use in patients with ARAS.
PROSPECTIVE RANDOMIZED CONTROLLED
TRIALS
Benefit of renal stenting over angioplasty alone.
Primary stenting of ARAS was compared to angioplasty
alone in one small RCT.11 The results of this trial were
comparable with those of a meta-analysis that compared
these two techniques.12 There was a 65% reduction in risk
of restenosis with stents at 6-month angiography, but there
was no difference in blood pressure or renal outcome.
Primary stenting thus showed a more favorable outcome
with fewer reinterventions than angioplasty for ARAS.13
Benefit of renal artery stenting vs surgery. Only one
RCT compared renal artery stenting vs open surgical revas-
cularization in patients with ARAS.14 Inclusion criteria
were severe hypertension and ARAS 70%. There was no
significant difference in treatment outcome (ie, blood pres-
sure, renal outcome, midterm patency, and complications).
But as surgery was associated with a longer duration of
hospitalization (18 days vs 10 days), the authors suggest chat renal artery stenting should be preferred to surgery in
atients who do not need concomitant aortic revasculariza-
ion.
In addition to this RCT, a large meta-analysis15 com-
aring the outcome of open surgical revascularization vs
ndovascular treatment showed that endovascular patency
eclined by 0.26% per month and that open revasculariza-
ion showed greater improvement for hypertension by 21%
95% confidence interval [CI], 9%-33%; P  .001) and for
enal function by 34% (95% CI, 18%-54%; P  .001) but
ith a higher surgical mortality, 3.1% (95% CI, 1.8%-4.4%;
 .01) that became insignificant when concomitant
ortic surgery was excluded. Despite the advantages of
pen revascularization, the attendant morbidity and mor-
ality of surgery ensures a significant role for renal artery
tenting in most patients. However, there will continue to
e a role for open renal artery revascularization in young
atients with severe RAS who are more likely to benefit
rom the durability of renal bypasses.
Comparison of renal artery stenting with medical
reatment alone. Comparison of renal artery stenting plus
edical treatment with medical treatment alone was avail-
ble in three RCTs (Table I). Two RCTs of limited
ower16,17 compared stent placement with medical treat-
ent in patients with ARAS with severe hypertension or
ecent impairment of renal function. These two studies did
ot show any significant improvement in renal function,
lood pressure outcome, or survival in patients with renal
tenting as compared with medical treatment alone.
A larger trial, Angioplasty and Stenting for Renal Artery
esions (ASTRAL) further questions the benefit of ARAS
tenting vs medical therapy alone.18 This RCT involved
06 patients with ARAS. Patients were enrolled if clinical
ndings (recent onset of hypertension or unexplained de-
reasing renal function) suggested a diagnosis of ARAS
onfirmed by duplex echography, computed tomographic
ngiography, or magnetic resonance angiography in at least
ne renal artery and if the physician was uncertain that the
atient would benefit from revascularization. ARAS sever-
ty was between 50% and 70% diameter-reducing lesion in
0% of the patients enrolled in the trial and exceeded 70% in
0% of them. After 5 years, change in renal function, mean
ystolic arterial pressure, and number of cardiovascular
vents or death did not differ significantly between the two
roups. This result was confirmed in a subgroup of patients
ith high-grade or bilateral ARAS. Among patients with
enal artery stenting, 4.2% suffered procedure-related ma-
or complications, including renal artery rupture, dissec-
ion, thrombosis, embolization, and worsening of renal
nsufficiency (Table I). The ASTRAL study concluded that
here was no advantage of revascularization as compared
ith medical treatment in patients with ARAS.
This trial was criticized because of its enrollment strat-
gy excluding patients who would likely benefit more from
enal stenting. In addition, 40% of patients with renal artery
tenting had moderate RAS between 50% and 70% diameter-
educing lesions, for which only limited benefit from revas-
ularization could be expected. Pressure gradient across the
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August 2011568 Kashyap et alstenosis was not measured in this study and there was no
core laboratory to validate the on-site visual estimates of
ARAS. There were also significant crossovers in this study
with only 359 of 403 patients randomized to renal artery
stenting who underwent the procedure, whereas 24 of 403
patients assigned tomedical treatment underwent interven-
tion. But when examined on a per-protocol analysis, there
was still no apparent benefit for renal artery stenting.
Randomized controlled trials: What have we learned?
The results of these three RCTs need to be considered
carefully in light of their design. The enrollment strategy of
the ASTRAL trial regarding the doubt of the effectiveness
of revascularization meant that clinicians were uncertain as
to whether they should intervene; consequently, they con-
sidered the randomization to be appropriate. Despite some
criticisms, almost all patients enrolled in these RCTs would
Table I. Randomized controlled trials comparing renal art
renal artery stenosis
References No. of patients
Inclusion
criteria
Renal ar
stenos
Ziakka et al16 36 with stents
46 with MT
Hypertension 74% (me
Bax et al17 64 with stents
76 with MT
Impaired renal
function
50%
Wheatley et al18 403 with stents
403 with MT
Uncontrolled
hypertension
or
unexplained
impaired
renal
function
50%
CI, Confidence interval; GFR, glomerular filtration rate; HR, hazard ratio;have been considered for renal artery stenting in normal Alinical practice. In the ASTRAL trial, the skills of the
hysicians performing renal stenting were not formally
ssessed, but their expertise was reflected in a technical
uccess rate of 95% and the rate of serious complications
as similar to that of other methodologically solid studies
ith rigorous record-keeping. In summary, these trials
rovide evidence that, in typical patients considered for
enal revascularization in today’s current clinical practice,
ntervention offers no clinical benefit and has some risk as
ompared to best medical treatment alone. It is possible,
owever, that renal artery stenting might benefit a minority
f patients with specific clinical presentations that were not
pecifically addressed in these RCTs.
Ongoing trials. Following the ASTRAL study, three
ngoing RCTs were designed to better assess renal and
ardiac outcomes after renal artery stenting. The Renal
tenting with medical therapy alone for atherosclerotic
Renal function
Follow-up
(mos) Outcomes
SCr: 2.3 mg/dL 48 Renal function improved
or stabilized in 64% of
patients with stents vs
70% with medication
alone (NS).
Hypertension cured or
improved in 78% of
patients with stents vs
71.4% in the medical
group (NS).
Creatinine clearance
80
mL/minute/1.73
m2
24 No difference in renal
event-free survival
(HR, 0.73; 95% CI,
0.33-1.61).
Procedure-related major
complications:
-2 procedure-related
deaths (3%)
-1 late death due to an
infected hematoma
-1 patient requested
dialysis secondary to
cholesterol embolism
GFR: 40
mL/minutes/
1.73 m2
34 No difference in renal
event-free survival,
GFR decline rate,
blood pressure,
cardiovascular events,
and survival.
Procedure-related major
complications (n 
17, 4.2%):
-5 kidney embolisms
-4 renal artery occlusions
-4 renal artery
perforations
-1 renal artery aneurysm
-3 peripheral embolisms
(amputations)
edical treatment alone; NS, not significant; sCr, serum creatinine.ery s
tery
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an)therosclerotic Revascularization study compares renal
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ite endpoint that includes death, dialysis, and doubling of
serum creatinine.19 The RADAR study compares best med-
ical treatment with best medical treatment plus renal artery
stenting in patients with hemodynamically relevant athero-
sclerotic RAS. The primary endpoint being the change in
estimated glomerular filtration rate between the two
groups during 12-month follow-up. Secondary endpoints
included technical success, change in average blood pres-
sure, and in left ventricular mass index. Finally, the Cardio-
vascular Outcomes with Renal Atherosclerotic Lesions
trial20 compares best medical treatment alone with renal
stenting on a composite heart, and vascular and renal
endpoint. In this trial, angiography and transluminal pres-
sure gradients were used to determine entry in the study
with a core laboratory using quantitative analysis. Patients
with a gradient20 mmHg and a renal artery35 mm in
diameter were considered for randomization.
Technical issues related to atherosclerotic renal artery
stenosis stenting. Renal artery stenting has improved over
recent years with small-platform, including a less traumatic
premounted low-profile stent on 0.014- or 0.018-inch
wire, less traumatic 2.5 to 4Fr shaft balloons, steerable
catheters, smaller puncture site, and rapid-exchange sys-
tems avoiding the need for long wires. Despite these signif-
icant improvements, ARAS stenting is not an easy proce-
dure and atheroembolic disease remains a major concern
with manipulation of the renal artery, which is a predictor
of embolic events.21 Distal embolic protection devices have
been logically used to avoid this complication. But in an
RCT, Cooper et al22 showed a decline in estimated glomer-
ular filtration rate in both groups of patients with and
without protection device. In this series, the only group
with no loss of glomerular filtration was receiving both the
embolic protection device and a platelet glycoprotein in-
hibitor (abciximab) suggesting a risk of intra-arterial
thrombosis triggered by the use of the embolic protection
device.
Refining the approach to renal artery revascula-
rization. As renal artery stenting falls short in these RCTs,
many nephrologists have moved toward a more conserva-
tive approach concerning ARAS (Table II) probably also to
counterbalance the attitude of aggressive cardiologists and
radiologists.23 Despite the difficulty in demonstrating ben-
efits of renal artery stenting in large groups that included
heterogeneous populations with a mixture of high- and
Table II. Reasons for skepticism regarding renal artery ste
1. Failure to define causal role of ARAS in disease syndromes such
2. Imprecise definition of ARAS with inclusion of subcritical ARA
3. Compensatory action of the nonstenotic kidney.
4. Advances in medical management: blockade of the renin-angiot
statins.
5. Complications of ARAS stenting: kidney embolism, occlusion,
6. Negative outcomes from randomized controlled trials.
ARAS, Atherosclerotic renal artery stenosis.low-risk patients, pathophysiological rationale and the pos-tive results of some small series have provided valid argu-
ents for renal stenting in a few patients with ARAS with
eteriorating renal function after receiving angiotensin-
onverting enzyme inhibitors or angiotensin-receptor
lockers and in patients with flash edema or uncontrolled
eart failure.24,25 In addition, many physicians recognize
hat some patients with severe stenosis particularly affecting
oth renal arteries or a solitary kidney should be considered
s potential candidates for renal artery stenting26 even if the
STRAL study showed no difference in outcome between
enal artery lesions of varying severity.
ONCLUSIONS
Recent evidence shows that optimal medical treatment,
ncluding statins and risk reduction factors should be the
referred option for most patients with ARAS. It is almost
ertain that the vast majority of typical patients now being
ubjected to renal artery stenting show no added benefits
egarding blood pressure and kidney function as compared
o best medical treatment alone. But it is equally important
o recognize that a minority of patients with rapidly pro-
ressive hypertension or renal insufficiency and flash pul-
onary edema, or with specific lesions such as bilateral
evere renal artery stenosis, or solitary kidney, do have a
enefit from restoring kidney perfusion.
EFERENCES
1. Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous
renal artery interventions by Medicare beneficiaries, 1996-2000. AJR
Am J Roentgenol 2004;183:561-8.
2. Steichen O, Amar L, Plouin PF. Primary stenting for atherosclerotic
renal artery stenosis. J Vasc Surg 2010;51:1574-80.
3. Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, et al.
Atherosclerotic renovascular disease in United States patients aged 67
years or older: risk factors, revascularization, and prognosis. Kidney Int
2005;68:293-301.
4. Hansen KJ; EdwardsMS, Craven TE, Cherr GS, Jackson SA, Appel RG,
et al. Prevalence of renovascular disease in the elderly: a population-
based study. J Vasc Surg 2002;36:443-51.
5. Dorros G, Jaff M, Mathiak L, Dorros II, Lowe A, Murphy K, et al.
Four-year follow-up of Palmaz-Schatz stent revascularization as treat-
ment for atherosclerotic renal artery stenosis. Circulation 1998;98:
642-7.
6. Chábová V, Schirger A, Stanson AW, McKusick MA, Textor SC.
Outcomes of atherosclerotic renal artery stenosis managed without
revascularization. Mayo Clin Proc 2000;75:437-44.
7. Uzu T, Inoue T, Fujii T, Nakamura S, Inenaga T, Yutani C, et al.
Prevalence and predictors of renal artery stenosis in patients with
myocardial infarction. Am J Kidney Dis 1997;29:733-8.
pertension or worsened renal function.
rials and lack of methods to assess renal hemodynamics.
system, effective antihypertensive drugs, antiplatelet agents and
ration or dissection of the renal artery, contrast nephropathy.nting
as hy
S in t
ensin
perfo8. Missouris CG, Belli AM, MacGregor GA. “Apparent” heart failure: a
syndrome caused by renal artery stenoses. Heart 2000;83:152-5.
11
1
2
2
2
2
2
2
JOURNAL OF VASCULAR SURGERY
August 2011570 Forbes and Ricco9. Drieghe B, Madaric J, Sarno G, Manoharan G, Bartunek J, Heyndrickx
GR, et al. Assessment of renal artery stenosis: side-by-side comparison of
angiography and duplex ultrasound with pressure gradient measure-
ments. Eur Heart J 2008;29:517-24.
10. Uzzo RG, Novick AC, Goormastic M, Mascha E, Pohl M. Medical
versus surgical management of atherosclerotic renal artery stenosis.
Transplant Proc 2002;34:723-5.
11. van de Ven PJ, Kaatee R, Beutler JJ, Beek FJ, Woittiez AJ, Buskens E,
et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic
renovascular disease: a randomised trial. Lancet 1999;353:282-6.
12. Leertouwer TC, Gussenhoven EJ, Bosch JL, van Jaarsveld BC, van Dijk
LC, Deinum J, et al. Stent placement for renal arterial stenosis: where
do we stand? A meta-analysis. Radiology 2000;216:78-85.
13. Hirsch AT,Haskal ZJ, Hertzer NR, Bakal CW, CreagerMA,Halperin JL, et
al. ACC/AHA2005. Practice guidelines for themanagement of patientswith
peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal
aortic): a collaborative report from the American Association for Vascular
Surgery/Society forVascular Surgery, Society forCardiovascularAngiography
and Interventions, Society for Vascular Medicine and Biology, Society of
Interventional Radiology, and theACC/AHATask Force onPracticeGuide-
lines (Writing Committee to Develop Guidelines for the Management of
Patients with peripheral Arterial Disease): endorsed by the American Associa-
tion of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung,
andBlood Institute; Society for VascularNursing; TransAtlantic Inter-Society
Consensus and Vascular Disease Foundation. Circulation 2006;113:e463-
654.
14. Balzer KM, Pfeiffer T, Rossbach S, Voiculescu A, Mödder U, Gode-
hardt E, et al. Prospective randomized trial of operative vs interven-
tional treatment for renal artery ostial occlusive disease (RAOOD). J
Vasc Surg 2009;49:667-74; discussion 674-5.
15. Abela R, Ivanova S, Lidder S, Morris R, Hamilton G. An analysis
comparing open surgical and endovascular treatment of atherosclerotic
renal artery stenosis. Eur J Vasc Endovasc Surg 2009;38:666-75.
16. Ziakka S, Ursu M, Poulikakos D, Papadopoulos C, Karakasis F, Kap-
eronis N, et al. Predictive factors and therapeutic approach of renovas-
cular disease: four years’ follow up. Ren Fail 2008;30:965-70.
2
accurately predict the natural history of any individual renal artery
lesion, nor recognize entirely which lesions are responsible for a
p
m
b
m
c
c
T
c
w
a
h
s7. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et
al. Stent placement in patients with atherosclerotic renal artery stenosis
and impaired renal function: a randomized trial. Ann Intern Med
2009;150:840-8.
8. ASTRAL Investigators,Wheatley K, Ives N, Gray R, Kalra PA,Moss JG,
et al. Revascularization versus medical therapy for renal-artery stenosis.
N Engl J Med 2009;361:1953-62.
9. Tobe S, Atri M, Perkins N, Pugash R, Bell CM. Renal atherosclerotic
revascularization evaluation (RAVE study): study protocol of a random-
ized trial [NCT00127738]. BMC Nephrol 2007;8:4.
0. Cooper CJ, Murphy TP,Matsumoto A, Steffes M, CohenDJ, Jaff M, et
al. Stent revascularization for the prevention of cardiovascular and renal
events among patients with renal artery stenosis and systolic hyperten-
sion: rationale and design of the CORAL trial. Am Heart J 2006;152:
59-66.
1. Scolari F, Ravani P, Pola A, Guerini S, Zubani R, Movilli E, et al.
Predictors of renal and patient outcomes in atherembolic renal disease:
a prospective study. J Am Soc Nephrol 2003;14:1584-90.
2. Cooper CJ, Haller ST, Colyer W, Steffes M, Burket MW, Thomas WJ,
et al. Embolic protection and platelet inhibition during renal artery
stenting. Circulation 2008;117:2752-60.
3. Textor SC, Lerman L, McKusick M. The uncertain value of renal
interventions: where are we now? JACC Cardvasc Interv 2009;2:
175-82.
4. Bloch MJ, Trost DW, Pickering TG, Sos TA, August P. Prevention of
recurrent pulmonary edema in patients with bilateral renovascular dis-
ease through renal artery stent placement. Am J Hypertens 1999;12(1
Pt 1):1-7.
5. Khosla S, White CJ, Collins TJ, Jenkins JS, Shaw D, Ramee SR. Effects
of renal artery stent implantation in patients with renovascular hyper-
tension presenting with unstable angina or congestive heart failure.
Am J Cardiol 1997;80:363-6.6. Safian RD, Madder RD. Refining the approach to renal artery revascu-
larization. JACC Cardvasc Interv 2009;2:161-74.EDITORS’ COMMENTARY
Thomas L. Forbes, MD, and Jean-Baptiste Ricco, MD, PhD, London, Ontario, Canada;
and Poitiers, France
It was expected that information resulting from recently com-
pleted randomized controlled trials would clarify the role of renal
artery interventions in patients with atherosclerotic renal artery
stenoses. Unfortunately, in this respect, we were left disappointed.
Concerns regarding such issues as inclusion criteria limited the
validity of these studies’ conclusions, leaving a persistent knowl-
edge gap into which our debaters step.
Although the authors were given separate charges, their con-
clusions are more similar than different. They both recognize the
need for further study and information to elucidate the role of renal
artery interventions. They recognize that we currently cannotatient’s hypertension or renal insufficiency. So instead of recom-
ending whether the majority or the minority of patients should
e intervened upon, they appropriately meet somewhere in the
iddle.
With the present uncertainty, the authors propose a multidis-
iplinary, collaborative approach to these often complicated clini-
al situations to arrive at decisions regarding individual patients.
hey propose a more aggressive approach in patients with specific
riteria, including progressive hypertension, renal insufficiency
ith flash pulmonary edema, bilateral severe renal artery stenoses,
nd stenoses with a solitary kidney. Until further information is
opefully obtained from ongoing trials, this selective approach
eems reasonable and most prudent.
